ogkoolrod retweeted
$LQDA at Jefferies - some more color on L606 regulatory pathway. They previously had agreement with FDA on 505b(2) pathway, but per the settlement can no longer reference some needed data for that in PH-ILD. So switched to 505b(1) pathway, which requires two studies - they simply added a PAH study. So adds some complexity and cost but not really much in the way of risk or timeline as studies will read out on similar timelines. Also now no automatic 30-month stay.
Re-iterated that existing UTHR patent speaks to "per breath" dosing, which L606 clearly sidesteps.
ogkoolrod retweeted
$LQDA Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH | Liquidia Corporation liquidia.com/news-releases/n…
$LQDA To be precise, Judge Andrews signed off on a stipulation (Doc 478/479) between the two legal teams. Because yesterday was the deadline to submit a proposed final remedy, they likely just agreed on the procedural formatting so the judge could formally enter the order—not a secret settlement or compromise. Since the document is sealed, we are in a holding pattern until the court unseals it or $LQDA drops an 8-K to confirm the exact scope of the injunction on Yutrepia's PAH launch.
12
1,567
$LQDA In the District of Delaware, local court rules typically give the parties 7 days to agree on redactions and file a public version of a sealed document on the docket.
However, I believe SEC rules require lqda to file an 8-K within 4 business days for any material event. We will almost certainly see an 8-K or press release from Liquidia explaining the terms of the stipulation well before the court's 7-day unsealing deadline.
$LQDA For anyone reading into the "Stipulation" on the Delaware docket today: he signed off on the stipulation (Doc 478), not a final order yet—but this is likely the agreed legal text for the final remedy following last week's deadline.
This is not to suggest UTHR backed down or make a deal. This is necessary legal plumbing so the judgment can be formally entered, enabling LQDA to take the fight to the Federal Circuit. Sealed for now while we wait for an 8-K or public release. LQDA needs this final judgment entered so they can officially launch their Federal Circuit appeal. This stipulation likely is just the lawyers finalizing the mandatory paperwork from last week's ruling.
The real question is the scope: if the injunction is narrowly tailored to PH-ILD, LQDA’s PAH carve-out strategy is officially cleared for launch. We wait for the unsealing.
2
10
2,201
ogkoolrod retweeted
valuation:
$LQDA — I spent some time reading the cases after the YUTREPIA decision. I’m not a patent lawyer, but I think the market is treating this as far more binary than the law—or economics—actually are.
Four cases matter:
1. Ferring v. Watson, 764 F.3d 1382 (Fed. Cir. 2014).
Ferring committed during litigation to amend its application to remove the infringing material.
Compare Norwich/Salix, where Norwich tried to carve out the patented indication after final judgment and lost.
Timing matters. LQDA has already said it intends to submit an NDA supplement removing PH-ILD. If that happens before final judgment, I think the facts look considerably better under Ferring than Norwich.
2. Jazz v. Avadel.
Avadel lost the patent case, yet the Delaware court refused to remove already-approved LUMRYZ from patients, ultimately imposing a 3.85% royalty on net sales.
Different statutory posture—Jazz does NOT override §271(e)(4)(A)—but it shows patent remedies involving approved drugs aren’t always economically binary.
3. Hikma v. Amarin — SCOTUS 2026.
Potentially the most interesting case for a PAH-only YUTREPIA.
SCOTUS unanimously held that inducement requires affirmative steps encouraging infringement. Knowledge that doctors may prescribe a skinny-labeled drug for a patented use isn’t enough.
That follows Warner-Lambert v. Apotex, 316 F.3d 1348: knowledge of off-label prescribing without promotion/encouragement isn’t inducement.
Meaning:
PAH-only label ≠ necessarily zero PH-ILD use.
LQDA couldn’t promote PH-ILD. But independent physician off-label prescribing is a different issue.
My prediction:
Judge Andrews probably applies §271(e)(4)(A). The statute is difficult to get around because PAH + PH-ILD currently sit in one NDA.
But PAH itself doesn’t infringe the ’327 patent.
My base case:
§271 applies → dual-indication approval goes away/becomes ineffective → FDA approves PAH-only labeling → YUTREPIA continues/returns for PAH.
So the key variable isn’t whether the PAH franchise disappears. It’s the gap: days, weeks or months between the judgment and FDA approval of PAH-only labeling?
Now valuation.
Rather than pretend I know the exact DCF, here’s how I think about the outcomes:
Hard bear: PAH + significant disruption: $35–45
Clean PAH-only: $50–60
PAH + organic physician-driven PH-ILD use: $60–80
Broader access + royalty/other remedy: $75–95
Full appellate win / PH-ILD restored: $90–120+
Those are my ranges, not Street targets.
But here’s the interesting part:
H.C. Wainwright removed PH-ILD entirely, assumes ~$1.1B peak PAH sales and gets $58/share.
Raymond James similarly removed PH-ILD/L606 and gets ~$53.
YUTREPIA is already doing real business: ~$170M Q2 revenue / ~$300M 1H26.
At ~$28, the market isn’t merely pricing PH-ILD at zero.
It’s pricing LQDA materially below published PAH-only valuations.
That’s the setup I like.
I don’t need LQDA to win everything.
PAH survives intact → substantial upside.
PAH + organic off-label PH-ILD → more upside.
PH-ILD restored on appeal → home run.
Ferring: timing matters.
Norwich: what can go wrong.
Jazz: remedies aren’t always binary.
Hikma: skinny label doesn’t necessarily mean zero off-label use.
At ~$28, I think the market is pricing something much closer to catastrophe than the range of outcomes I see.
Long $LQDA
$LQDA fantastic and thurough take highlighting where we are and the potential paths forward
Joining @MartinShkreli and longing $LQDA
Emergency deep dive is out.
Martin, I'd be honored to hear your take on the report, and btw, thanks for putting Liquidia on my radar.
financial6pack.substack.com/…
1
14
1,549
Im no expert on evaluation. How do you calculate this? $lqda @ $17/share puts MC @ ~1.5B.
Is this assuming a worse case on all legal fronts? Needham price target $70/share w 50% royalty which seems unlikely. Is this an "IF there's a complete erasure of l606 and rejection of sNDA carveout"?
5
1,334
ogkoolrod retweeted
9/ And there is another piece I think the market may be underappreciating.
Liquidia isn't merely a one-product patent trade.
YUTREPIA was created using its PRINT particle-engineering platform, which allows Liquidia to engineer particles with precise size, shape and composition to improve deposition in the lung.
There's also L606, its twice-daily extended-release inhaled treprostinil program, plus the broader potential applications of PRINT.
I think there's some genuinely interesting technology optionality there.
exactly the point i made yesterday
Sometimes the ugliest headlines make for the most interesting entry points.
Case in point: $LQDA — Liquidia.
The stock closed at $30.26 after falling 57% yesterday and is now around $25.32 pre-market.
I spent this morning going through the decision, the numbers, some of the relevant patent case law, and the new sell-side work.
My conclusion: the headline looks considerably worse than the range of plausible economic outcomes.
Here’s how I’m thinking about it 🧵👇
6
712
Somehow I'm still green on the year on $LQDA because I took some profits in $80 s even though I added back shares in $70 s and $31 yesterday. This obviously sucks, but if liquidia can continue to sell Yutrepia seamlessly (which I think 99% likely, but therein lies the fear), I think this is oversold. I'm not rushing to add a bunch more yet though. There's a lot of psychology to cycle through the tape first. This morning was margin liquidations, which was the first part, and hopefully marks the low. But still lots of fear and uncertainty and bag holders. It won't be a quick organic bounce IMO
In my opinion, ANY resolution on damages near term would be a major boost to the stock. However, I don't expect parties to come to agreement this week, so it's likely back to court we go, and timeline extended. It's trading down here on fears that the drug gets removed entirely and the uncertainty around timeline and process of other damages, but when the market agrees (either by sentiment or info) that Yutrepia continues to sell seamlessly for PAH, even if damages aren't resolved, I think the stock floats back higher somewhat.
All that to say, I think we'll look back in time at these prices in the $20 s and wish we bought a good chunk for our ports and just chilled.
ogkoolrod retweeted
the $LQDA buying opportunity is significant. stock will double as it becomes clear that the court ruling is not existential. drug is approved for PAH. never been a drug pulled over a patent. compulsory royalty of 10% would double stock instantly. courts will not harm patients.
$LQDA certainly faces hurdles and obstacles now and moving forward - that is undeniable, but some of the fear and reaction seen on finx is extreme and alludes to an outcome that is far worse than the court has the authority to mandate. Even with extreme legal gymnastics I have not seen a scenario where "whole market ban" "revoked fda approvals" "corporate death sentences" exist. What UTHR requests does not impact what legal paths forward Andrew's has. Does he have statutory authority to issue an injunction against Yutrepia's core PAH indication? Can Andrews retroactively un-approve active NDA applications?Jeffs already confirmed if necessary they would file sNDA supplment to remove PH-ILK indication.
While the ruling is an administrative and legal hurdle for the PH-ILD indication, the court cannot destroy Liquidia's PAH floor, revoke its FDA NDA, or stop the company's next-gen pipeline (L606).
And, if any of these details are misunderstood by me, please sincerely let me know.
1
16
1,954
This conflates the off-patent active ingredient (treprostinil) with proprietary delivery technologies, while wildly overstating $UTHR legal reach. United Therapeutics does not own treprostinil as a chemical compound. Anyone can legally make and sell treprostinil (which Liquidia already does with its generic Treprostinil Injection). UTHR cannot file a blanket challenge against "everything Liquidia does", Patent litigation under Hatch-Waxman requires enforcing specific, issued patent claims. L606 is a liposomal, sustained-release formulation administered via a smart nebulizer (Q12H twice-daily dosing). It operates on completely separate IP, distinct clinical trial data, and its own proprietary drug delivery mechanism. UTHR cannot simply "shut down L606" just because it uses the treprostinil molecule.
Today's ruling does not touch Yutrepia's approval for PAH. Even if UTHR refused a voluntary royalty deal and Judge Andrews placed a restriction on PH-ILD, Liquidia retains full legal rights to launch and sell Yutrepia in the multi-hundred-million-dollar PAH market. Liquidia does not rely on UTHR "agreeing" to a settlement. Under federal patent precedent, if a court determines that public health interests (patients unable to tolerate Tyvaso DPI) outweigh an injunction, the judge can order a compulsory running royalty regardless of whether UTHR agrees.
I don't see how $LQDA survives this unless they make a royalty deal with $UTHR that allows them to keep selling and developing Yutrepia and L606. Both their drugs are the same treprostinil. The only difference is the delivery method such as liposomal suspension. I would have to think they could be challenged on everything they do now from $UTHR.
More $LQDA thoughts..
Judge Andrews' decision on the ’327 patent pertains strictly to the PH-ILD indication expansion, leaving Yutrepia’s core addressable market in Pulmonary Arterial Hypertension (PAH) legally untouched. Even under a restricted ILD scenario, the baseline commercial floor in PAH remains intact. Because Tyvaso DPI carries significant tolerability issues (severe cough and throat irritation), public health interests favor keeping a better-tolerated therapy like Yutrepia available for PH-ILD patients. Thus, the court forcing an ongoing running royalty—rather than issuing a permanent commercial ban—remains the most probable legal endpoint, time will tell. L606 offers twice-daily (Q12H) dosing compared to Tyvaso’s 4x daily requirement, representing a true next-generation therapeutic platform. As Tim pointed out, future growth into broader cardiopulmonary indications (COPD, Raynaud's phenomenon) provides a long-term growth runway decoupled from the current ’327 patent dispute. Andrews' ruling creates short-term headline noise and volatility, it does not alter the fundamental thesis. A court-mandated royalty on PH-ILD, coupled with an unencumbered launch in PAH and the long-term rollout of L606, keeps the overarching multi-year upside for Liquidia fully intact.
Been buying since single digits, cost basis now in 20's after significant adds today. nfa
$LQDA The sell-off is a severe overreaction to an indication-specific hurdle, creating a compelling risk-reward setup:
The ’327 patent decision impacts PH-ILD only—leaving YUTREPIA’s primary, multi-hundred-million-dollar PAH market untouched. Under post-eBay patent law and public health interest (patients unable to tolerate Tyvaso DPI), the final remedy strongly favors a manageable, single-digit royalty or an emergency stay pending appeal rather than a permanent commercial lockout. With YUTREPIA’s high gross margins able to easily absorb a royalty drag—and next-generation L606 securing the long-term moat—Liquidia’s underlying commercial thesis remains completely intact, for now.











